KR102200656B1 - 마이크로스피어를 포함하는 개선된 창상 치료 조성물 - Google Patents
마이크로스피어를 포함하는 개선된 창상 치료 조성물 Download PDFInfo
- Publication number
- KR102200656B1 KR102200656B1 KR1020157009202A KR20157009202A KR102200656B1 KR 102200656 B1 KR102200656 B1 KR 102200656B1 KR 1020157009202 A KR1020157009202 A KR 1020157009202A KR 20157009202 A KR20157009202 A KR 20157009202A KR 102200656 B1 KR102200656 B1 KR 102200656B1
- Authority
- KR
- South Korea
- Prior art keywords
- microspheres
- wound
- pharmaceutical composition
- wounds
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 138
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 230000029663 wound healing Effects 0.000 title description 24
- 206010052428 Wound Diseases 0.000 claims abstract description 145
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 145
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 96
- 230000005484 gravity Effects 0.000 claims abstract description 51
- 239000002562 thickening agent Substances 0.000 claims abstract description 35
- 239000004793 Polystyrene Substances 0.000 claims description 86
- 229920002223 polystyrene Polymers 0.000 claims description 86
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 54
- 239000008215 water for injection Substances 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 30
- 230000001684 chronic effect Effects 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 208000000558 Varicose Ulcer Diseases 0.000 claims description 4
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 235000011187 glycerol Nutrition 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000011550 stock solution Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000011324 bead Substances 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000011162 core material Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 108010007568 Protamines Chemical class 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- WLZPCFOGJNCCRJ-UHFFFAOYSA-M 4-ethenyl-1-ethylpyridin-1-ium;bromide Chemical compound [Br-].CC[N+]1=CC=C(C=C)C=C1 WLZPCFOGJNCCRJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012679 Diabetic neuropathic ulcer Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- -1 Polypropylene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700362P | 2012-09-13 | 2012-09-13 | |
| US61/700,362 | 2012-09-13 | ||
| PCT/IL2013/050774 WO2014041543A1 (en) | 2012-09-13 | 2013-09-12 | Improved wound healing compositions comprising microspheres |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150082207A KR20150082207A (ko) | 2015-07-15 |
| KR102200656B1 true KR102200656B1 (ko) | 2021-01-11 |
Family
ID=50277729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157009202A Active KR102200656B1 (ko) | 2012-09-13 | 2013-09-12 | 마이크로스피어를 포함하는 개선된 창상 치료 조성물 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9370533B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2895209B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6104390B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102200656B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013316718B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015005335B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2883455C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2895209T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2748805T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20191804T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE047212T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2895209T (cg-RX-API-DMAC7.html) |
| MX (1) | MX359713B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2895209T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2895209T (cg-RX-API-DMAC7.html) |
| RS (1) | RS59410B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014041543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107205624B (zh) * | 2014-10-29 | 2019-08-06 | 光谱Md公司 | 用于组织分类的反射式多光谱时间分辨光学成像方法和装备 |
| CN110573066A (zh) | 2017-03-02 | 2019-12-13 | 光谱Md公司 | 用于多光谱截肢部位分析的机器学习系统和技术 |
| WO2020123724A1 (en) | 2018-12-14 | 2020-06-18 | Spectral Md, Inc. | Machine learning systems and methods for assessment, healing prediction, and treatment of wounds |
| JP7186298B2 (ja) | 2018-12-14 | 2022-12-08 | スペクトラル エムディー，インコーポレイテッド | 高精度マルチアパーチャスペクトルイメージングのためのシステムおよび方法 |
| US10783632B2 (en) | 2018-12-14 | 2020-09-22 | Spectral Md, Inc. | Machine learning systems and method for assessment, healing prediction, and treatment of wounds |
| US10740884B2 (en) | 2018-12-14 | 2020-08-11 | Spectral Md, Inc. | System and method for high precision multi-aperture spectral imaging |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614310A (en) * | 1994-11-04 | 1997-03-25 | Minnesota Mining And Manufacturing Company | Low trauma wound dressing with improved moisture vapor permeability |
| US5861149A (en) * | 1997-06-04 | 1999-01-19 | Polyheal Ltd. | Methods for wound treatment |
| IL136583A0 (en) | 1998-10-23 | 2001-06-14 | Polyheal Ltd | Compositions of microspheres for wound healing |
| EP1368354A1 (en) * | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| US7465463B2 (en) * | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
| JP2009525975A (ja) * | 2006-01-31 | 2009-07-16 | ヴァション，デイビッド | 多細胞生物の組織の治癒を促進するための組成物及びその方法 |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
-
2013
- 2013-09-12 RS RSP20191288 patent/RS59410B1/sr unknown
- 2013-09-12 ES ES13838041T patent/ES2748805T3/es active Active
- 2013-09-12 US US14/427,747 patent/US9370533B2/en active Active
- 2013-09-12 JP JP2015531687A patent/JP6104390B2/ja active Active
- 2013-09-12 MX MX2015002816A patent/MX359713B/es active IP Right Grant
- 2013-09-12 CA CA2883455A patent/CA2883455C/en active Active
- 2013-09-12 PL PL13838041T patent/PL2895209T3/pl unknown
- 2013-09-12 AU AU2013316718A patent/AU2013316718B2/en active Active
- 2013-09-12 KR KR1020157009202A patent/KR102200656B1/ko active Active
- 2013-09-12 HR HRP20191804TT patent/HRP20191804T1/hr unknown
- 2013-09-12 BR BR112015005335-1A patent/BR112015005335B1/pt active IP Right Grant
- 2013-09-12 HU HUE13838041A patent/HUE047212T2/hu unknown
- 2013-09-12 PT PT138380415T patent/PT2895209T/pt unknown
- 2013-09-12 WO PCT/IL2013/050774 patent/WO2014041543A1/en not_active Ceased
- 2013-09-12 DK DK13838041.5T patent/DK2895209T3/da active
- 2013-09-12 EP EP13838041.5A patent/EP2895209B1/en active Active
- 2013-09-12 LT LT13838041T patent/LT2895209T/lt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013316718B2 (en) | 2016-09-29 |
| BR112015005335A8 (pt) | 2018-01-30 |
| RS59410B1 (sr) | 2019-11-29 |
| LT2895209T (lt) | 2019-10-25 |
| EP2895209A1 (en) | 2015-07-22 |
| ES2748805T3 (es) | 2020-03-18 |
| HRP20191804T1 (hr) | 2019-12-27 |
| PT2895209T (pt) | 2019-10-28 |
| EP2895209A4 (en) | 2016-04-20 |
| BR112015005335B1 (pt) | 2020-03-10 |
| DK2895209T3 (da) | 2019-10-21 |
| HK1212638A1 (en) | 2016-06-17 |
| US20150231170A1 (en) | 2015-08-20 |
| PL2895209T3 (pl) | 2020-01-31 |
| HUE047212T2 (hu) | 2020-04-28 |
| JP6104390B2 (ja) | 2017-03-29 |
| MX2015002816A (es) | 2015-05-15 |
| KR20150082207A (ko) | 2015-07-15 |
| MX359713B (es) | 2018-10-08 |
| US9370533B2 (en) | 2016-06-21 |
| CA2883455A1 (en) | 2014-03-20 |
| EP2895209B1 (en) | 2019-07-17 |
| WO2014041543A1 (en) | 2014-03-20 |
| JP2015528492A (ja) | 2015-09-28 |
| BR112015005335A2 (pt) | 2017-07-04 |
| CA2883455C (en) | 2020-01-28 |
| AU2013316718A1 (en) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102132543B1 (ko) | 양이온성 살생물제를 포함하는 페트롤라툼-계 조성물 | |
| Khorasani et al. | Aloe versus silver sulfadiazine creams for second-degree burns: a randomized controlled study | |
| KR102200656B1 (ko) | 마이크로스피어를 포함하는 개선된 창상 치료 조성물 | |
| JP6778219B2 (ja) | 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用 | |
| JP2021520373A (ja) | Ｃｇｒｐを阻害する際に使用するための神経毒素 | |
| JP2019206544A (ja) | 次亜塩素酸ナトリウムを含む抗炎症溶液 | |
| Serafini et al. | Recent patents on medicinal plants/natural products as a therapeutic approach to wounds and burns healing | |
| US20220249734A1 (en) | Powdered collagen wound care compositions | |
| EP3087990B1 (en) | Gel-forming powder comprising sulfamonomethoxine and chitosan for treating wounds | |
| RU2286781C2 (ru) | Способ лечения химических ожогов пищевода у детей | |
| HK1212638B (en) | Improved wound healing compositions comprising microspheres | |
| US20250367224A1 (en) | Galactose and fucose monosaccharides for re-epithelialization and treating lesions | |
| EP4659751A1 (en) | Galactose and fucose monosaccharides for re-epithelialization and treating lesions | |
| CN112316108A (zh) | 促进及治疗慢性伤口愈合的组合物和方法 | |
| KR101607229B1 (ko) | 말기름을 함유하는 상처 치료용 조성물 | |
| Katual et al. | Advancements in Treatment of Laceration by Chitosan Coated Flexible Liposomes of Mupirocin: A current prospective | |
| Sar | Development and characterisation of metformin loaded film with flaxseed gel for acceleration of healing process of burn wounds: an approach for tissue regeneration | |
| Poorahmary Kermany | Carbopol hydrogels for topical administration: treatment of wounds | |
| CN117617500A (zh) | 一种适用于术后恢复的功能型配方粉及其制备方法和用法 | |
| Palácio et al. | WOUND HEALING EFFECTS OF Β-LAPACHONE-LOADED LIPOSOMAL HYDROGEL BASED ON BACTERIAL CELLULOSE AND HYDROXYETHYLCELLULOSE | |
| Ternullo | Nanocarriers for tailored skin delivery: More than just the carriers? | |
| Zagórska-Dziok et al. | Hydrogel-Based Active Substance Release Systems for Cosmetology and Dermatology Application: A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150409 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180907 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200213 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20201013 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210105 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210105 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20231228 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20241226 Start annual number: 5 End annual number: 5 |